Why NewLink Genetics (NLNK) Stock Is Gaining Today
at The Street - Thu Aug 14, 10:31AM CDT
NewLink Genetics (NLNK) shares are climbing after announcing that it was ready to start human trials for an Ebola vaccine.
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
Why A Short Covering Rally Might Come for NewLink Genetics (NLNK) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 8:38AM CDT
Why A Short Covering Rally Might Come for NewLink Genetics (NLNK) Stock
Sarepta Should Shut Up About Ebola, Focus on Job No. 1
at The Street - Wed Aug 06, 11:07AM CDT
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.
NewLink Genetics Corporation, Through Its Wholly Owned Subsidiary, BioProtection Systems Corporation, Secures a Letter Contract From the Defense Threat Reduction Agency for Testing and Evaluation of Ebola Virus Vaccine
Marketwire - Tue Aug 05, 6:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), through its wholly owned subsidiary, BioProtection Systems Corporation (BPS), today announced a letter contract with the United States Defense Threat Reduction Agency (DTRA) for studies that will bring an Ebola vaccine licensed from the Public Health Agency of Canada closer to human clinical trials. The letter contract is for $1.0 million with additional funding subject to final negotiation and will fund Investigational New Drug (IND)-enabling pre-clinical toxicology studies and includes the manufacture of clinical materials.
NewLink Genetics Corporation Reports Second Quarter 2014 Financial Results
Marketwire - Tue Aug 05, 6:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the second quarter of 2014 and progress in its development programs.
NewLink Genetics to Present at the XVIth International Congress of Virology
Marketwire - Mon Jul 28, 6:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), today announced that an oral presentation on efficacy of influenza vaccines modified with the alpha-Gal carbohydrate will be given at the XVIth International Congress of Virology, part of the International Union of Microbiological Societies (IUMS), July 28, 2014 in Montreal, Canada.
Are Investors Wrong About NewLink Genetics?
George Budwell, The Motley Fool - Motley Fool - Wed Jul 02, 4:00PM CDT
Clinical-stage biotechs are frequently targeted by short-sellers because these types of companies can (and sometimes do) crater overnight. By the same token, a positive clinical or regulatory catalyst can send shares ripping higher in the blink of an...
NewLink (NLNK) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:35AM CDT
NewLink (NLNK) Shares March Higher, Can It Continue?
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 23, 7:38AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018
M2 - Wed Jun 18, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s9wr9/global) has announced the addition of the "2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018" report to their offering. A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period. The analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market. The report, 2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Key Leading Countries 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Pipeline Analysis 17. Vendor Landscape 18. Key Vendor Analysis Companies Mentioned: - Agenus - Bavarian - Dendreon - GlaxoSmithKline - Novartis International - AFFiRiS - Argos Therapeutics - Celldex Therapeutics - CEL-SCI - Cytos Biotechnology - GlobeImmune - NewLink Genetics - NovaRx - Oncothyreon - TVAX Biomedical - TapImmune - Vical - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4s9wr9/global
Biotech Equities Ahead of Market -- Research on Vertex Pharma, NewLink Genetics, ImmunoGen, and Synta Pharma
PR Newswire - Thu Jun 05, 6:20AM CDT
On Wednesday, June 04, 2014, the NASDAQ Composite ended at 4,251.64, up 0.41%, the Dow Jones Industrial Average finished the day 0.09% higher at 16,737.53, and the S&P 500 closed at 1,927.88, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, and the index has advanced 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), NewLink Genetics Corp. (NASDAQ: NLNK), ImmunoGen Inc. (NASDAQ: IMGN) and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Free technical research on VRTX, NLNK, IMGN and SNTA can be downloaded upon signing up at:
NewLink Genetics Demonstrates Continuing IDO Pathway Inhibitor Progress at ASCO 2014 Annual Meeting
Marketwire - Thu Jun 05, 1:34AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, demonstrated continuing progress with its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor program at the American Society for Clinical Oncology (ASCO) 2014 annual meeting. In a series of presentations, NewLink researchers and collaborators presented multiple on-going clinical studies with its IDO pathway inhibitor candidates, expanding the immuno-oncology regimens being evaluated to include combinations with other immunotherapies, cancer vaccines, and chemotherapy. These presentations were highlighted by ASCO as trials in progress posters, demonstrating continued interest for innovative ongoing studies in IDO- mediated checkpoint inhibition.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
3 Biotechs Bucking the Downtrend
George Budwell, The Motley Fool - Motley Fool - Tue Mar 25, 10:30AM CDT
Mr. Market savaged the biotech sector yesterday. Specifically, 92% of small-caps were losers, 94% of mid-caps painted the tape red, and large caps saw a single winner, Gilead Sciences . Given the broad-based downtrend in the sector, I think it's...
NewLink Genetics to Present Data at the AACR 2014 Annual Meeting
Marketwire - Tue Mar 25, 6:15AM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced that two poster presentations highlighting its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor programs, will be presented at the upcoming American Association of Cancer Research (AACR) meeting which will take place April 5-9, 2014 in San Diego, CA.